EMA reviews cancer medicine Zydelig

View source ↗

Summary

The EMA reviews the cancer medicine Zydelig (idelalisib) for potential safety concerns and evaluates available data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Apple Disease
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Small Lymphocytic Lymphoma

Drugs mentioned

• Zydelig (idelalisib)